AzTrials
AzTrials

Sleep Apnea, Obstructive; Post-Traumatic Stress DisordersEarly Phase 1NCT02699138

Obstructive Sleep Apnea and Arousal Threshold in Patients With Post-traumatic Stress Disorder

A Early Phase 1 study testing Trazodone and Epiglottic catheter in people with Sleep Apnea, Obstructive; Post-Traumatic Stress Disorders, run by University of California, San Diego at 1 site in United States.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

Obstructive sleep apnea (OSA) has traditionally been attributed only to a collapsible upper airway. However, it is increasingly recognized that multiple additional non-anatomical mechanisms contribute to the disease. Read more about this study

Who is it for?
Ages 18 to 70 yearsHealthy volunteers can take part
What is being tested?
Trazodone and Epiglottic catheter
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
0 participants
Where
1 siteUnited States
Study dates
Oct 2021to Dec 2022
Phase
Early Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Normal sleep study aside from elevated AHI
  • Prior home sleep test (HST) or polysomnogram with results consistent with mild, moderate, or severe sleep apnea. If a sleep study has not been performed in the past, the participant will be offered an HST and included if OSA is confirmed on HST.
  • PTSD as diagnosed by psychiatrist, psychologist, or other licensed mental health professional

Who cannot join

  • Any known cardiac (apart from treated hypertension), symptomatic pulmonary (including asthma), renal, neurologic (including epilepsy), neuromuscular, or hepatic disease.
  • Pregnant women.
  • History of hypersensitivity to Afrin, Lidocaine, or Trazodone
  • History of bleeding diathesis and/or gastrointestinal bleeding.
  • Daily use of any sedative medications that may affect sleep or breathing, including benzodiazepines, opioids, or hypnotics.
  • A psychiatric disorder, other than mild depression or PTSD; e.g. schizophrenia, bipolar disorder, major depression, panic or anxiety disorders.
Show all 10Show fewer
  • Substantial cigarette (>5/day), alcohol (>3oz/day) or use of illicit drugs.
  • More than 10 cups of beverages with caffeine (coffee, tea, soda/pop) per day.
  • Subjects with oxyhemoglobin desaturations to <70% on the initial PSG (Aim 1) will be excluded from participation in Aim 2.
  • Current, everyday use of continuous positive airway pressure therapy.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of California San Diego

    San Diego, California, 92103

Other trials in United States

About this study

Official title: Obstructive Sleep Apnea and Arousal Threshold in Patients With Post-traumatic

Obstructive sleep apnea (OSA) has traditionally been attributed only to a collapsible upper airway. However, it is increasingly recognized that multiple additional non-anatomical mechanisms contribute to the disease. Higher rates of OSA in patients with post-traumatic stress disorder (PTSD) than in those without PTSD have been reported however the mechanism behind this increased prevalence has not been investigated. Our hypothesis is that patients with PTSD have a predisposition to OSA due to a lower respiratory arousal threshold (wake up too easily) than patients without PTSD. The goal of this project will be to study and compare the ArTH in patients with PTSD and those without. In addition, we plan to see whether medications can be used to increase the arousal threshold and treat OSA in patients with PTSD.

Read the detailed description

Obstructive sleep apnea (OSA) is a clinically relevant disease that is associated with cardiovascular, metabolic, and neurocognitive consequences. OSA is a very common disease; the Wisconsin Sleep Cohort Study found that OSA affects 2% of women and 4% of men aged 30-60. However, these data predate the obesity epidemic and use of more modern diagnostic equipment, such that more recent studies have reported prevalences of moderate to severe OSA as high as 24% in women and 49% in men.

The prevalence of OSA has been found to be particularly high in patients suffering from post-traumatic stress disorder (PTSD). One study of veterans with combat related PTSD found that 67.3% of this population was diagnosed with OSA after undergoing polysomnography. This finding is consistent with those of Mysliwiec et al who found rates of OSA in 63% of post-deployment soldiers and 51% of active duty soldiers. Despite increased recognition of this association, there has been little progress in establishing a pathophysiological link between the two diseases, and no study to our knowledge examining the possibility that PTSD might drive the development of OSA. Furthermore, individuals with PTSD have been found to have significantly lower compliance with continuous positive airway pressure (CPAP) therapy than the general population, with claustrophobia, mask discomfort, and air hunger as the most commonly cited reasons for non-adherence. Despite this, studies have shown both benefit in sleep quality and PTSD related nightmares with OSA treatment. Alternative OSA therapies are therefore particularly important in this group, but will rely on determination of targets other than those treated by CPAP.

While a propensity towards upper airway collapse, as seen in obesity, has classically been considered the principle determinate of OSA pathogenesis, more recent work has shown that non-anatomical variables including the ventilatory arousal threshold (ArTH) are also important. During wakefulness pharyngeal dilator muscles remain active to maintain airway patency however during sleep these muscles lose activity in all individuals but in those with OSA airway collapse occurs and results hypoxia and hypercapnia. Both accumulation of carbon dioxide and increased negative pressure can cause recruitment of the upper airway dilator muscles resulting in pharyngeal patency if sleep is maintained. Cortical arousal during apnea for most individuals represents a protective mechanism as the airway is restored with resolution of hypoxia and hypercarbia. However individuals with low ArTH (individuals who wake easily) do not have sufficient time for accumulation of respiratory stimuli, recruitment of pharyngeal muscles is then unable to occur which results in disruption of sleep. ArTH is variable amongst individuals and is dependent on the magnitude of negative intrathoracic pressure tolerated before awakening occurs and is independent from other factors.

A central feature of PTSD is a state of persistent hyperarousal that chronically persists following a traumatic event. Individuals with PTSD have been found to have important physiologic changes of the hypothalamic-pituitary axis (HPA) and sympathoadrenal system including increased levels of sympathetic neurotransmitters such as norepinephrine and increased activity of α2-adrenergic and glucocortocoid receptors. Both the HPA and sympathetic nervous system are associated with attention and arousal. Prolonged activation of these systems has been shown to induce important biochemical changes associated with disordered sleep. Indeed, studies in norepinephrine deficient knockout mice have demonstrated that increased stimulus is required to induce cortical arousal in the norepinephrine deficient mice and results in higher acoustic ArTH when compared to controls. Our hypothesis is that patients suffering from PTSD will have a lower ArTH when compared to subjects without PTSD. This work is significant because if lower ArTH is associated with PTSD these patients may benefit from therapies that raise the ArTH.

Prior studies have indicated that trazodone, a serotonin reuptake inhibitor commonly used for insomnia and occasionally for depression, may raise the arousal threshold without suppressing upper airway muscle activity. This medication therefore presents a potentially attractive alternative treatment to CPAP therapy for patients with OSA related to a low arousal threshold.

Being tested
Trazodone, Placebo, Epiglottic catheter
Medical subject headings
Sleep Apnea Syndromes, Stress Disorders, Post-Traumatic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • TrazodoneDrug

    100mg of trazodone to be administered orally once.

  • PlaceboDrug

    Compounded sugar pill

  • Epiglottic catheterDevice

    Catheter that can be placed through the nose to a position behind the tongue to monitor for upper airway obstruction and to measure changes in pressure below the obstruction.

Study groups in NCT02699138
Study groupRoleWhat they receive
TrazodoneExperimentalTo determine effect of trazodone on quality of sleep as measured by apnea hypopnea index in subjects with obstructive sleep apnea and PTSD on routine overnight polysomnogram.
Receives: Drug: Trazodone; Device: Epiglottic catheter
PlaceboPlacebo comparatorTo compare placebo outcomes against administration of trazodone
Receives: Drug: Placebo; Device: Epiglottic catheter

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Respiratory arousal threshold

    Arousal threshold will be measured by epiglottic catheter placement during routine polysomnograph. Respiratory arousal threshold is measured by standard criteria and determined by difference in the terminal pressure measured prior to cortical arousal on EEG and the baseline epiglottic pressure.

    Measured: 8 hours

  2. Apnea hypopnea index

    Severity of obstructive sleep apnea measured by the apnea hypopnea index. Measured by standard sleep scoring criteria.

    Measured: 8 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Mar 2016 (estimated)
  2. Study startOct 2021 (estimated)
  3. Primary completionDec 2022 (estimated)
  4. Study completionDec 2022 (estimated)

Why it stopped: Research fellow left institution

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Crossover
Masking
Single blind
Who is masked
Participant
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02699138
Sponsor's protocol ID
UCSD151424
Status last verified
Jul 2019
First submitted
24 Feb 2016
Last updated
10 Jul 2019
Results posted
No
FDA-regulated drug
No
FDA-regulated device
Yes

Questions about this trial

What is this clinical trial studying?

A Early Phase 1 study testing Trazodone and Epiglottic catheter in people with Sleep Apnea, Obstructive; Post-Traumatic Stress Disorders, run by University of California, San Diego at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 10 Jul 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Respiratory arousal threshold (time frame: 8 hours). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jul 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in